Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma. A randomized phase III DeCOG trial
Eigentler, T.K., Gutzmer, R., Hauschild, A., Heinzerling, L., Schadendorf, D., Nashan, D., Hölzle, E., Kiecker, F., Becker, J., Sunderkötter, C., Moll, I., Richtig, E., Pönitzsch, I., Pehamberger, H.,Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw225
Date:
June, 2016
File:
PDF, 905 KB
english, 2016